Are Chemfab Alkalis Ltd latest results good or bad?

1 hour ago
share
Share Via
Chemfab Alkalis Ltd's latest Q4 FY26 results show a sequential sales growth of 9.74% to ₹74.78 crores, but a significant year-on-year decline of 19%. While the company reported a net profit of ₹0.48 crores, this is a drastic drop of 105.22% compared to the previous year, raising concerns about the sustainability of profitability amid ongoing operational challenges.
Chemfab Alkalis Ltd's latest financial results for Q4 FY26 reflect a complex operational landscape. The company reported net sales of ₹74.78 crores, which represents a sequential growth of 9.74% from the previous quarter, indicating some recovery in sales. However, this figure marks a significant year-on-year decline of 19.00% compared to ₹92.32 crores in Q4 FY25, highlighting ongoing challenges in demand within the commodity chemicals sector.
The net profit for the quarter turned positive at ₹0.48 crores, a notable turnaround from a loss of ₹4.45 crores in the previous quarter. This shift suggests some operational stabilization, yet the year-on-year comparison indicates a drastic drop of 105.22%, raising concerns about the sustainability of this profitability. Operating margins improved to 11.39%, a substantial increase from the previous quarter's 2.85%. Despite this sequential improvement, the margin is still below the 14.44% achieved in the same quarter last year, reflecting ongoing pricing pressures and cost challenges. The company's reliance on other income was significant, contributing ₹2.80 crores, which accounted for 227.64% of profit before tax. This reliance raises questions about the quality of earnings and the sustainability of the reported profit, as core operations alone would have resulted in a loss. Overall, Chemfab Alkalis is navigating a challenging operational environment characterized by structural issues and cyclical headwinds. The company has seen an adjustment in its evaluation, which reflects these ongoing challenges and the need for a closer examination of its financial health and operational strategies moving forward.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News